Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Mervat Azab"'
Publikováno v:
Zagazig University Medical Journal.
Autor:
Mervat Azab, Ahmed Mokhtar Ahmed, Maha Atfy, Tamer Hassan, Eman Mohammed Abd El Aziz, Ahmed Mohamed Baraka
Publikováno v:
Zagazig University Medical Journal.
Background: Measurement of minimal residual disease (MRD) reflects the overall response to therapy, and could be used to refine the treatment of acute lymphoblastic leukemia (ALL). MRD studies by flowcytometry rely on panels of antibodies (Abs) to de
Publikováno v:
Zagazig University Medical Journal.
Publikováno v:
Zagazig University Medical Journal.
Publikováno v:
Journal of Indian College of Cardiology. 7:42-47
Background/aims The aim of this work is to discuss the role of cystatin C (CyC) as an early predictor biomarker of coronary artery disease (CAD) in subclinical atherosclerotic and hypertensive patients. Subjects and methods 120 patients were included
Publikováno v:
Afro-Egyptian Journal of Infectious and Endemic Diseases. 5:143-151
Publikováno v:
Zagazig University Medical Journal. 20:1-7
At this study we aimed to detect the prevalence of JAK2 V617F mutation in various myeloproliferative neoplasms (MPNs) that represent a major advance in molecular understanding of CMPN disorders in order to identify its diagnostic value. In this study
Publikováno v:
The Egyptian Journal of Haematology. 42:81
Background Acute lymphoblastic leukemia (ALL) is a biologically heterogeneous disorder. Clinical parameters, immunophenotype, cytogenetic factors, and minimal residual disease (MRD) are among currently used factors in risk stratification and therapy